A Phase 3 Clinical Testing of 0.5% ADX-102 for Allergic Conjunctivitis

Trial Profile

A Phase 3 Clinical Testing of 0.5% ADX-102 for Allergic Conjunctivitis

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Reproxalap (Primary)
  • Indications Allergic conjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2017 According to an Aldeyra Therapeutics media release, this trial is expected to begin in the first half of 2018. Results are expected to be announced in the second half of 2018.
    • 21 Jun 2017 New trial record
    • 14 Jun 2017 Accordin to an Aldeyra Therapeutics media release, based on the data from another trial (see profile 277242) the company plans to initiate this trial following discussion with the regulatory authorities in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top